FDA Approves Rusfertide, First-in-Class Hepcidin Mimetic for Polycythemia Vera

The FDA approved rusfertide (Mimrylo), a first-in-class treatment for adults living with polycythemia vera. This novel agent is indicated for the treatment of erythrocytosis in adult patients with this chronic blood cancer. Developed by Takeda, rusfertide is the first approved therapy for polycythemia vera that mimics hepcidin, a natural hormone regulating systemic iron homeostasis. By limiting iron availability required to manufacture red blood cells, this subcutaneous weekly therapy directly targets the biology of red blood cell overproduction. This approval marks a treatment paradigm shift for patients whose disease has not been adequately controlled with existing therapies.

Key Takeaways: Understanding Polycythemia Vera and Rusfertide

• Pathological Threat of Erythrocytosis: Polycythemia vera is characterized by chronic, clonal overproduction of red blood cells, increasing blood viscosity and thickness.
• Thromboembolic Complications: Uncontrolled hematocrit above 45% is linked to life-threatening thrombotic events, including stroke and pulmonary embolism.
• Severe Patient Symptom Burden: Elevated red blood cells cause complex, often invisible symptoms impairing daily quality of life, including severe fatigue, pruritus, difficulty concentrating, and night sweats.
• Elevated Mortality Risk: Patients with uncontrolled hematocrit despite standard therapies face a four times higher risk of cardiovascular death.

Managing polycythemia vera requires keeping the hematocrit below 45% to mitigate cardiovascular risks. This has historically required frequent phlebotomy, a burdensome procedure removing blood from a vein to lower red blood cells. Unfortunately, an estimated 78% of patients continue to experience uncontrolled hematocrit despite phlebotomies and cytoreductive therapies. This persistent instability leaves patients vulnerable to cardiovascular events, placing a massive burden on daily routines. By mimicking the natural iron-regulating hormone hepcidin, rusfertide keeps hematocrit under control and reduces red blood cell overproduction, offering an innovative, non-chemotherapeutic alternative.

The approval of rusfertide is supported by the global, randomized, double-blind, placebo-controlled Phase 3 VERIFY trial (NCT05210790). The trial evaluated weekly, subcutaneously self-administered rusfertide in 293 adults with polycythemia vera who remained phlebotomy-dependent despite standard treatments, including phlebotomy, hydroxyurea, interferon, or ruxolitinib. Patients were randomized 1:1 to receive weekly rusfertide or placebo over a 32-week period. Rusfertide was initiated at 19 mg subcutaneously and titrated to maintain hematocrit below 45%.

The primary efficacy endpoint of the VERIFY trial was the proportion of patients who achieved a clinical response during weeks 20 to 32, defined as the absence of phlebotomy eligibility. To meet phlebotomy eligibility, patients required either a confirmed hematocrit of 45% or greater that was at least 3% higher than baseline, or a hematocrit of 48% or greater. The trial successfully met all primary and secondary endpoints. Specifically, 76.9% of patients in the rusfertide group required no phlebotomies during the evaluation period, compared to only 32.9% in the placebo group. Furthermore, patients receiving rusfertide demonstrated sustained hematocrit control below 45% and a significant reduction in fatigue, as measured by the PROMIS Fatigue Short Form 8a.

Key Takeaways: Nursing Considerations for Rusfertide Management

• Platelet Monitoring for Thrombocytosis: Rusfertide can cause new or worsening thrombocytosis, with platelets generally plateauing by week 8. Nurses must monitor complete blood counts (CBC) every 2 to 4 weeks after initiation and during dose modifications.
• Injection-Site Reaction Support: The most common adverse reaction is injection-site reactions (56%), including erythema, pruritus, pain, and swelling. Nurses should advise patients to use ice, topical corticosteroid creams, antihistamines, or analgesics as needed.
• Screening for Anemia: Anemia is the second most common adverse reaction (16%). Nurses should track hemoglobin and hematocrit closely to differentiate between controlled therapeutic response and clinical anemia.
• Advise on Breastfeeding Cessation: Due to the potential for serious adverse reactions in breastfed infants, such as impaired iron absorption, lactating patients must not breastfeed during treatment and for 30 days after the final dose.
• Embryo-Fetal Toxicity Precautions: Rusfertide may cause fetal harm. Prior to initiating treatment, nurses must verify pregnancy testing in females of reproductive potential and counsel them to use effective contraception during therapy and for 30 days post-final dose.

Oncology nurses are essential partners in managing patients on rusfertide therapy. Through comprehensive patient education on self-administration, proactive monitoring of laboratory parameters, and diligent side-effect management, nurses can help maximize the clinical benefits of this first-in-class agent. By reducing phlebotomy dependence, improving debilitating symptoms like fatigue, and maintaining tight hematocrit control, rusfertide represents an outstanding advancement in supportive and therapeutic care for patients navigating the challenges of polycythemia vera.

References

1. FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder. FDA News Release. Silver Spring, MD: US Food and Drug Administration; August 28, 2026. Accessed August 31, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder
2. Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera. Press Release. Osaka, Japan and Cambridge, MA: Takeda Pharmaceutical Company Limited; August 28, 2026. Accessed August 31, 2026. https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/